Biological API Drug Manufacturing Market Size
Biological API Drug Manufacturing Market reached US$ 39.8 billion in 2026 and is expected to reach US$ 136.9 billion by 2033, growing with a CAGR of 16.3% during the forecast period 2026-2033.
The biological API involved in the fermentation of microorganisms and cultured in a substrate to produce a substance that is used for treating disease eg: antibiotics, steroids, and vaccines, and other biological molecules used for the production of vaccines and genetically modified vaccines.
Market Summary
| Metrics | Details |
| CAGR | 16.3% |
| Size Available for Years | 2024-2033 |
| Forecast Period | 2026-2033 |
| Data Availability | Value (US$) |
| Segments Covered | By Manufacturing Type, By Expression Platforms, By Application, and By Region |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Fastest Growing Region | Asia Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For More Insights Request Free Sample
Biological API Drug Manufacturing Market Drivers
- The surge in demand for biotechnology products and ongoing research by biopharmaceutical companies on therapeutic diseases majorly cancer, followed by autoimmune and cardiovascular diseases are driving the global biological API drug manufacturing.
- The rise in disease population in therapeutic categories will boost the innovation in novel biologic substances is additionally amplifying the growth of the market.
Market Segmentation Analysis
- Global biological API drug manufacturing market is segmented by manufacturing type, expression platform, application, and region. Manufacturing type includes In-House manufacturing and API Contract manufacturing, expression platform includes mammalian cell culture, microbial fermentation, and other expression platforms. By application includes monoclonal antibody (mAb) therapies, vaccines, insulin therapies, interferon therapies, and growth hormones.
- API contract manufacturing dominates the global biological API drug manufacturing market during the forecast period due to its extensive usage of CMO’s by small and medium companies due to lack of complex manufacturing capabilities, capital-intensive nature of the business, and high profitability associated with contracting with CMO for both clinical and commercial stage manufacturing.
Market Geographical Share
- The global biological API drug manufacturing market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa.
- North America dominates the global biological API drug manufacturing market during the forecast period due to the high presence of key manufacturing service providers (CMO) in the region, shift from chemical synthesis to biological API, government approvals for production of novel drugs, and high investments by the pharmaceuticals companies in R&D of Drugs.
Competition Landscape
- New Product launches and mergers between key players for the development of novel technologies using Biological API are driving the global Biological API Drug Manufacturing Market.
- Major market players in the Biological API Drug Manufacturing Market are Lonza, Boehringer Ingelheim BioXcellence, Celltrion, DSM Biologics, Samsung BioLogics, Fujifilm Diosynth Biotechnologies, and Others.
Recent Developments
- April 2026 – Samsung BioLogics expands large-scale biologics API manufacturing capacity
Samsung BioLogics accelerated expansion of biologics manufacturing infrastructure and advanced bioprocessing capabilities to support rising global demand for monoclonal antibodies, biosimilars, and next-generation biologic APIs. - April 2026 – Lonza Group AG strengthens biologics API production and cell therapy manufacturing services
Lonza expanded integrated biologics manufacturing solutions with increased investment in mammalian cell culture, microbial fermentation, and commercial-scale biologic API production technologies. - March 2026 – FUJIFILM Diosynth Biotechnologies advances biopharmaceutical API manufacturing expansion projects
FUJIFILM Diosynth expanded global CDMO capabilities for recombinant proteins, vaccines, and biologic APIs through facility upgrades and advanced continuous bioprocessing initiatives. - March 2026 – Boehringer Ingelheim BioXcellence enhances biologics development and commercial manufacturing operations
Boehringer Ingelheim BioXcellence strengthened biologic API manufacturing services with expanded upstream and downstream processing capabilities supporting biopharma outsourcing demand. - February 2026 – Celltrion increases biologics and biosimilar production investments
Celltrion expanded biologic drug substance manufacturing and biosimilar production capacity to support global commercialization of antibody therapeutics and autoimmune disease treatments. - February 2026 – DSM Biologics advances sustainable biologic API manufacturing technologies
DSM Biologics expanded bioprocess optimization and sustainable manufacturing initiatives focused on improving biologic production efficiency, scalability, and environmental performance.
Target Audience
• Equipment Suppliers/ Buyers
• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Research Institutes
• Research Professionals
• Emerging Companies
• Manufacturer
